Company: PFSA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004396
Chunk: 558

Company: Profusa, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 558
---
 Section 2(a) of the Securities Act of 1933,
as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012.

Changes
in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting
(as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting, other than as described above.

ITEM 9B. OTHER INFORMATION.

During the period covered
by this Annual Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement
or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as
amended).

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS.

Not applicable.

50

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Directors and Executive Officers

Our directors and officers are as follows:

    Name
     
    Age
     
    Title
  
    Jack Stover
     
    69
     
    Co-Founder, Director, Chief Executive Officer
  
    Fred Knechtel
     
    63
     
    Co-Founder, Director, Chief Financial Officer
  
    Peter O’Rourke
     
    50
     
    Chairman of the Board, Independent Director 
  
    Ed Johnson
     
    62
     
    Independent Director 
  
    Lauren Chung
     
    49
     
    Independent Director 

Jack Stover - Co-Founder, Director and Chief
Executive Officer

Jack Stover has served as
our Chief Executive Officer and director since inception. From June 2016 to November 2020, Mr. Stover served as president and chief executive
officer of Interpace Biosciences, Inc., a publicly-traded small cap life sciences company providing complex molecular analysis for the
early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. From December 2015 until June 2016, Mr.
Stover served as interim president and chief executive officer of Interpace Biosciences,